Press releases

Learn more
19 / 06 / 2017
Ipsen and its partner Exelixis announce independent radiology committee review confirms results fro...
16 / 06 / 2017
Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spas...
08 / 06 / 2017
Ipsen initiates share buy-back program to cover its free performance share allocation plan
07 / 06 / 2017
Combined Shareholders’ Meeting of IPSEN S.A. held on 7 June 2017

Share price

Learn more

Ipsen Investor Day

Investor-Day-2017

FACTS AND FIGURES 2016

Cover of registration document 2016

key figures 2016

Diagram Key figures 2016
Diagram Key figures 2016Learn more

Agenda

Ipsen Investor Day

May 11, 2017

London, United Kingdom

...

Contact

Investor Relations

Phone : +44 (0)1 753 627 721

Phone : +33 (0)1 58 33 53 31

Send an email

About Ipsen

Learn more

2017 financial objectives

 

>+18%
Specialty Care sales

 

>+4%
Consumer Healthcare sales

 

> 24%
Core Operating margin

Learn more
Last update 23/02/2017